Leprosy

Current Opinion in Neurology

Volumn 13, Issue 3, 2000, Pages 317-322

  Haimanot, Redda Tekle ^a   Melaku, Zenebe ^a  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

DEVELOPED COUNTRY; HUMAN; LEPROSY; MYCOBACTERIUM LEPRAE; NERVE FUNCTION; NERVE INJURY; REVIEW; SCHWANN CELL;

HUMANS; LEPROSY;

EID: 0034041636     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200006000-00015     Document Type: Review

References (63)

1. 1 Weekly Epidemiological Record. Global leprosy situation. 1999; 38:313-320. This record has the latest statistics on the global leprosy situation. It contains prevalence and detection of leprosy by regions and countries as well as numbers of patients cured with MDT.
2. 2 Jiang J, Watson JM, Zhang GC, Wei XY. A field trial of detection and treatment of nerve function impairment in leprosy - report from National POD Pilot Project. Lepr Rev 1998; 69:367-375.
3. 3 Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev 1999; 70:140-159. A carefully monitored study assessing the frequency of nerve function impairments in relation to the leprosy classification of the patients and the peripheral nerves affected.
4. 4 Abel L, Sanchez FO, Oberti J, Thuc NV, Hoa LV, Lap VD, et al. Susceptibility to leprosy is linked to the human NRAMP1 Gene. J Infect Dis 1998; 177:133-145.
5. 5 Rambukkana A, Salzer JL, Yurchenco PD, Tuomanen EL. Neural targeting of Mycobacturium leprae mediated by the G domain of the laminin-alpha 2 chain. Cell 1997; 88:811-821.
6. 6 Rambukkana A, Yamada H, Zanazzi G, Mathus T, Salzer JL, Yurchenco PD, et al. Role of alpha-dystroglycan as a schwann cell receptor for Mycobacterium leprae. Science 1998; 282:2076-2079.
7. 7 Yamada H, Chiba A, Endo T, Kobata A, Anderson LV, Hori H, et al. Characterization of Dystroglycan-Laminin in Peripheral Nerve. J Neurochem 1996; 66:1518-1524.
8. 8 Oldfors A. Macrophages in peripheral nerves: an ultrastructural and enzyme histochemical study on rats. Acta Neuropathol (Berl) 1980; 49:43-49.
9. 9 Scollard DM. M. leprae: infection of vascular and lymphatic endothelial cells of the epineurium and perineurium in experimental lepromatous neuritis. Nohon Hansenbyo Gakkai Zasshi 1999; 68:147-155.
10. 10 Griffin JW, George EB, Chaudhry V. Wallerian degeneration in peripheral nerve disease. Bailliere's Clin Neurol 1996; 5:65-75.
11. 11 Turk JL, Curtis J, De Blaquiere G. Immunopathology of nerve involvement in leprosy. Indian J Lepr 1991; 63:483-491.
12. 12 Bourrel P. Surgical rehabilitation. Lepr Rev 1991; 62:241-254.
13. 13 Abulafia J, Vignale RA. Leprosy: pathogenesis updated. Int J Dermatol 1999; 38:321-324. An extensive updated review of the pathogenesis of leprosy with emphasis on immunologic mechanisms.
14. 14 Solomon S, Kurian N, Ramadas P, Rao PS. Incidence of nerve damage in leprosy patients treated with MDT. Int J Lepr Other Mycobact Dis 1998; 66:451-456.
15. 15 Jacob M, Mathai R. Diagnostic efficacy of cutaneous nerve biopsy in primary leprosy. Int J Lepr 1998; 56:56-60.
16. 16 Suneetha S, Arunthathi S, Job A, Date A, Kurian N, Chacko CJ. Histological studies in primary neuritic leprosy: changes in the nasal mucosa. Lepr Rev 1998; 69:358-366.
17. 17 Suneetha S, Arunthathi S, Chandi S, Kurian N, Chacko CJ. Histological studies in primary neuritic leprosy: changes in the apparently normal skin. Lepr Rev 1989; 69:351-357.
18. 18 Manandhar R, LeMaster JW, Roche PW. Risk factors for erythema nodosum leprosum. Int J Lepr Other Mcyobact Dis 1999; 67:270-278.
19. 19 Roche PW, Le Master J, Butlin CR. Risk factors for type 1 reactions in leprosy. Int J Lepr Other Mycropact Dis 1997; 65:450-455.
20. 20 Lockwood DN, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 1999; 67:6-12.
21. 21 Hamerlinck FF, Klatser PR, Walsh DS, Bos JD, Walsh GP, Faber WR. Serum neopterin as a marker for reactional states in leprosy. FEMS Immunol Med Microbiol 1999; 24:405-409.
22. 22 Schon T, Gebre N, Sundqvist T, Habtemariam HS, Engeda T, Britton S. Increased levels of nitric oxide metabolites in urine from leprosy patients in reversal reaction. Lepr Rev 1999; 70:52-55.
23. 23 Hari L, Suryanarayanan D, Thomas A, Joseph P. An assessment of the value of midfinger smears in multibacillary leprosy patients. Lepr Rev 1999; 70:47-51.
24. 24 Singh N, Bhatia A, Arora VK, Bhattacharya SN. Fine-needle aspiration cytology of lepromatous leprosy. Lepr Rev 1998; 69:145-150.
25. 25 Nadkarni NS, Rege VL. Significance of histopathological classification in leprosy. Indian J Lepr 1999; 71:325-332.
26. 26 Wang L, Izumi S, He H, Fujiwara N, Saita N, Yano I, et al. Serodiagnosis of Hansen's disease/leprosy by enzyme-linked immunosorbent assay using cord factor (trehalose 6,6′-dimycolate) as an antigen, Nohon Hansenbyo Gakkai Zasshi 1999; 68:165-174.
27. 27 Kampirapap K. Mycobacterium leprae particle agglutination in diagnosis and monitoring treatment of leprosy. J Med Assoc Thai 1999; 82:1020-1024.
28. 28 van Beers S, Harta M, Klatser PR. Seroprevalence rate of antibodies to phenolic glycolipid-I among school children as an indicator of leprosy endemicity. Int J Lepr Other Mcyobact Dis 1999; 67:243-249.
29. 29 Tomimori-Yamashita J, Nguyen TH, Maeda SM, Flageul B, Rotta O, Cruaud P. Anti-phenolic glycolipid-I (PGL-I) determination using blood collection on filter paper in leprosy patients. Rev Inst Med Trop São Paulo 1999, 41:239-242.
30. 30 Buhrer SS, Smits HL, Gussenhoven GC, Ingen CW Van, Klatser PR. A simple dipstick assay for the detection of antibodies to phenolic glycolipid-I of Mycobacterium leprae. Am J Trop Med Hyg 1998; 58:133-136.
31. 31 Causative organism and host response [Workshop Report]. International Leprosy Congress, Beijing, 7-12 September 1998. Lepr Rev 1999; 70:95-102.
32. 32 Spierings E, de Vlieger M, Brand A, Klatser PR, Ottenhoff TH. Antibodies to sulfatide in leprosy and leprosy reactions. Am J Trop Med Hyg 1999; 61:495-499.
33. 33 Samant G, Shetty VP, Uplekar MW, Antia NH. Clinical and electrophysiological evaluation of nerve function impairment following cessation of multidrug therapy in leprosy. Lepr Rev 1999; 70:10-20. This is a useful study that compared the results of electrophysiological studies with those of physical examinations in the evaluation of nerve function impairment.
34. 34 Anderson AM, Croft RP. Reliability of Semmes Weinstein monofilament and ballpoint sensory testing, and voluntary muscle testing in Bangladesh. Lepr Rev 1999; 70:305-313.
35. 35 Ladhani S. Leprosy disabilities: the impact of multidrug therapy (MDT). Int J Dermatol 1997; 36:561-572.
36. 36 Meima A, Saunderson PR, Gebre S, Desta K, van Oortmarssen GJ, Habbema JD. Factors associated with impairments in new leprosy patients: The AMFES Cohort. Lepr Rev 1999; 70:189-203.
37. 37 Habtemariam H. Viability and drug sensitivity of M. leprae isolated from long-term WHO/MDT treated multibacillary leprosy patients. Lepr Rev 1999; 70:43-46.
38. 38 Gupta UD, Katoch K, Singh HB, Natrajan M, Sharma V, Katoch VM. Detection of viable organisms in leprosy patients treated with multidrug therapy. Acta Leprol 1999; 11:89-92.
39. 39 Sharma A, Sharma VK, Rajwanshi A, Das A, Kaur I, Kumar B. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR. Lepr Rev 1999; 70:281-286.
40. 40 WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser 1998; 874:1-43.
41. 41 Waters MFR. Is it Safe to Shorten Multidrug Therapy for Lepromatous (LL and BL) Leprosy to 12 months? Lepr Rev 1998; 69:110-111.
42. 42 Lynch P. Multidrug therapy [letter]. Lepr Rev 1999; 70:70-71.
43. 43 Ramu G. Single-dose rifampicin, oflaxicin and minocycline (ROM) therapy for single leprosyl [letter]. Lepr Rev 1998; 69:78-82.
44. 44 Katoch VM. Is there a microbiological rationale for single-dose treatment of leprosy? [editorial], Lepr Rev 1998; 69:2-5.
45. 45 Britton WJ. The management of leprosy reversal reactions. Lepr Rev 1998; 69:225-234.
46. 46 Croft RP, Richardus JH, Smith WC. Field treatment of acute nerve function impairment in leprosy using standardized corticosteroids regimen - first year's experience with 100 patients. Lepr Rev 1997; 68:316-325.
47. 47 Bernink EH, Voskens JE. Study on the detection of leprosy reactions and the effect of prednisone on various nerves, Indonesia. Lepr Rev 1997; 68:225-232.
48. 48 Disease and Disease Control. [Workshop Report] International Leprosy Congress, Beijing, 7-12 September 1998. Lepr Rev 1999; 70:78-84.
49. 49 Annas GJ, Elias S. Thalidomide and the Titanic. Reconstructing the technology tragedies of the twentieth century. Am J Public Health 1999; 89:98-101.
50. 50 Lary JM, Daniel KL, Erickson JD, Roberts HE, Moore CA. The return of thalidomide: can birth defects be prevented? Drug Saf 1999; 21:161-169.
51. 51 Sampaio EP, Moraes MO, Nery JA, Santos AR, Matos HC, Sarno EN. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum. Clin Exp Immunol 1998; 111:300-308.
52. 52 Welsh O, Gomez M, Mancias C, Ibarra-Leal S, Millikan LE. Pharmacology and therapeutics: a new approach to type 2 leprosy reaction. Int J Dermatol 1999; 38:931-933.
53. 53 Gupte MD, Vallishayee RS, Arantharaman DS, Nagaraju B, Sreevatsa , Balasubramanyam S, et al. Comparative leprosy vaccine trial in South India. Indian J Lepr 1998; 70:369-388.
54. 54 Kukarni HR, Zodpey SP. Differential protective effect of Bacillus Calmette-Guerin vaccine against multibacillary leprosy in Nagpur, India [in process citation]. Public Health 1999; 113:311-313.
55. 55 Zodpey SP, Bansod BS, Shrikhande SN, Maldhure BR, Kulkarni SW. Protective effect of Bacillus Calmette-Guerin (BCG) against leprosy: a population-based case-control study in Nagpur, India. Lepr Rev 1999; 70:287-294.
56. 56 Talwar GP. An immunotherapeutic vaccine for multibacillary leprosy. Int Rev Immunol 1999; 18:229-249. The paper reports on the results of Mycobacterium w. vaccine used as an adjunct to chemotherapy in urban and rural leprosy control centres in India.
57. 57 Sharma P, Kar HK, Misra RS, Mukherjee A, Kaur H, Mukherjee R, Rani R. Induction of lepromin positivity following imuno-chemotherapy with Mycobacterium w. vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with candidate antileprosy vaccine. Int J Lepr Other Mycobact Dis 1999; 67:259-269.
58. 58 Whitty C. Mycobacterium w. immunotherapy in leprosy [editorial]. Lepr Rev 1998; 69:222-224.
59. 59 Kazen RO. Management of plantar ulcers in leprosy. Lepr Rev 1999; 70:63-69.
60. 60 Zhen B. Effect of self-care on 56 cases of leprosy [in Chinese]. China Lepr J 1998; 14:159-160.
61. 61 Zheng Z, et al. Effect of self-care in 856 persons affected with leprosy [in Chinese]. China Lepr J 1998; 14:154-156.
62. 62 Duerkson F. Surgery of common paralytic conditions. Lepr Rev 1998; 69:390-396.
63. 63 Jacobson RR, Krahenbuhl JL. Leprosy [seminar]. Lancet 1999; 353:655-660.